Earnings ·
Palvella Therapeutics reported a net loss of $21.9 million, or $1.52 per share, for the quarter ended June 30, 2026…
PVLAPalvella Therapeutics, Inc.
Palvella Therapeutics reported a net loss of $21.9 million, or $1.52 per share, for the quarter ended June 30, 2026, compared to a $9.5 million loss in the prior year period. Cash and short-term investments totaled $250.6 million as of June 30, 2026. The company submitted the first module of its rolling New Drug Application (NDA) for QTORIN™ rapamycin to treat microcystic lymphatic malformations and remains on track to complete the submission in the second half of 2026. Additionally, Palvella plans to initiate a Phase 3 trial for cutaneous venous malformations in Q4 2026 and a Phase 2 trial for QTORIN™ pitavastatin in H2 2026. The company is preparing for a potential standalone U.S. commercial launch of QTORIN™ rapamycin in the first half of 2027 if approved. Palvella Therapeutics, Inc. operates in the biopharmaceutical industry, developing and commercializing novel therapies for rare skin diseases and vascular malformations.